查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1662635

2030 年 miRNA 定序和检测市场预测：按产品类型、miRNA 类型、样本类型、技术、应用、最终用户和地区进行的全球分析

miRNA Sequencing and Assay Market Forecasts to 2030 - Global Analysis By Product Type (miRNA Analysis Software, miRNA Sequencing Services and Other Product Types), miRNA Type, Sample Type, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球 miRNA 定序和检测市场预计在 2024 年达到 3.975 亿美元，到 2030 年达到 8.864 亿美元，复合年增长率为 14.3%。

miRNA定序是一种用于分析生物样本中微型RNA（miRNA）表现图谱的高绩效技术。 miRNA 检测是测量 miRNA 丰度或活性的实验技术，通常使用 qRT-PCR、微阵列和次世代定序等技术。这些工具将有助于了解 miRNA 在疾病、发育和细胞反应中的作用。

根据美国国家生物技术资讯中心 (NCBI) 于 2021 年 7 月发表的一篇论文，测量 miRNA（miR-195-5p、miR-23a-3p、miR-423-5p）可以实现对 COVID-19 的早期诊断，准确率达 99.9%。

个人化医疗需求日益增长

由于 miRNA 在基因调控和疾病机制中发挥着至关重要的作用，对个人化医疗的需求不断增长正在推动市场的发展。透过了解个体的基因特征，miRNA 分析可以实现标靶治疗的精准医疗。个人化医疗的转变将推动诊断、药物开发和针对特定患者的照护的进步，从而增加 miRNA 定序技术在客製化医疗解决方案中的应用。

复杂资料分析

市场上复杂的资料分析面临着许多挑战，例如高计算成本、需要先进的生物资讯学专业知识以及资料解释中可能存在的错误。这种复杂性可能导致不一致、可重复性差以及难以提取有意义的生物学见解。这可能会导致基于 miRNA 的诊断和治疗方法的采用延迟，从而阻碍个人化医疗和临床应用的进展。

慢性病增加

由于 miRNA 参与调节与癌症、糖尿病和心血管疾病等疾病相关的各种通路，慢性病的日益普及推动了市场的发展。 miRNA分析有助于早期诊断、监测疾病进展和製定个人化治疗计划。对精准诊断和治疗策略的日益增长的需求推动了 miRNA 定序技术在慢性病管理和研究中的发展。

定序和分析高成本

市场上定序和分析的高成本限制了其应用，特别是在较小的研究实验室和医疗保健机构。这种经济障碍阻碍了基于 miRNA 的诊断和治疗方法的广泛采用和应用。此外，高成本减缓了研究和创新的步伐，推迟了个人化医疗的潜在突破，并减少了改善一系列疾病患者治疗结果的机会。

COVID-19 的影响

新冠疫情导致研究计划延迟、实验室使用受限以及资源被重新分配至紧急的疫情相关需求，从而扰乱了市场。这阻碍了正在进行的研究并阻碍了基于 miRNA 的诊断和治疗方法的发展。然而，这场大流行凸显了快速准确诊断的重要性，并加速了人们对未来全球健康危机中病毒感染检测和个人化治疗方法的 miRNA 技术的兴趣。

预测期内，自体免疫疾病领域预计将实现最大幅度成长

miRNA 正在被研究作为狼疮和多发性硬化症等自体免疫疾病的潜在生物标记。 miRNA 分析有助于了解疾病机制、确定治疗目标和开发早期诊断工具。随着研究的进展，基于miRNA的检测有望在自体自体免疫疾病的个人化治疗中发挥重要作用，提高诊断的准确性和治疗效果。

预计製药和生物技术公司在预测期内将实现最高复合年增长率

预计製药和生物技术公司部门将在预测期内实现最高成长率。 miRNA在基因调控中发挥重要作用，其表现图谱可为多种疾病提供见解，包括癌症和神经系统疾病。定序技术的进步使得 miRNA 表现的高通量分析成为可能，为医药市场中新的治疗方法和改进的患者特异性治疗策略提供了潜力。

比最大的地区

在预测期内，北美预计将占据最大的市场占有率，因为它拥有先进的医疗保健基础设施和对个人化医疗的高度重视。该地区受益于 miRNA 技术在学术和临床领域的广泛应用，癌症、感染疾病和遗传疾病的研究也不断取得进展。政府资助以及生物技术公司和研究机构之间的合作进一步推动了市场的扩张。

复合年增长率最高的地区

预计预测期内亚太地区将呈现最高的复合年增长率。特别是，人们对基于 miRNA 的研究的投入不断增加，以了解 miRNA 在基因调控、疾病机制和治疗应用中的作用。此外，个人化和精准医疗的转变正在推动对 miRNA 定序的需求，因为 miRNA 可以提供有关个别基因特征和疾病感受性的宝贵见解。

免费客製化服务

订阅此报告的客户可享有以下免费自订选项之一：

  • 公司简介
    • 对其他市场参与企业（最多 3 家公司）进行全面分析
    • 主要企业的 SWOT 分析（最多 3 家公司）
  • 地理细分
    • 根据客户兴趣对主要国家进行市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争性基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第 2 章 前言

  • 概述
  • 相关利益者
  • 研究范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二手研究资料资讯来源
    • 先决条件

第三章 市场走势分析

  • 介绍
  • 驱动程式
  • 限制因素
  • 机会
  • 威胁
  • 产品分析
  • 技术分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第 4 章 波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球 miRNA 定序和检测市场（按产品类型）

  • 介绍
  • miRNA分析软体
    • 定序耗材
    • 文库製备试剂套件
  • miRNA定序服务
  • 其他的

6. 全球 miRNA 定序与检测市场（依 miRNA 类型）

  • 介绍
  • 保守的 miRNA
  • 非保守 miRNA
  • 肿瘤细胞
  • 发育 miRNA

7. 全球 miRNA 定序和检测市场（按样本类型）

  • 介绍
  • 血液/血清/血浆
  • 组织样本
  • 尿液和唾液
  • 细胞株

8. 全球 miRNA 定序和检测市场（按技术）

  • 介绍
  • 顺序
    • 新一代定序（NGS）
    • 微阵列
    • 定量聚合酵素链锁反应（qPCR）
  • 奈米孔定序
  • 桑格序列测定。
  • 单分子即时（SMRT）定序

9. 全球 miRNA 定序和检测市场（按应用）

  • 介绍
  • 癌症
  • 多聚谷氨酰胺疾病
  • 心血管疾病
  • 思觉失调症
  • 自体免疫疾病
  • 感染疾病
  • 神经系统疾病
  • 其他的

第 10 章。

  • 介绍
  • 学术研究所
  • 製药和生物技术公司
  • 医院和诊断实验室
  • 合约研究组织 (CRO)
  • 其他的

第 11 章。

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十二章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十三章 公司概况

  • Illumina, Inc.
  • Thermo Fisher Scientific, Inc.
  • Qiagen NV
  • Agilent Technologies, Inc.
  • Macrogen, Inc.
  • Bio-Rad Laboratories, Inc.
  • Takara Bio, Inc.
  • Exiqon A/S
  • Zymo Research Corporation
  • New England Biolabs, Inc.
  • Roche Diagnostics
  • Promega Corporation
  • Luminex Corporation
  • Boster Biological Technology
  • Bioo Scientific
Product Code: SMRC28496

According to Stratistics MRC, the Global miRNA Sequencing and Assay Market is accounted for $397.5 million in 2024 and is expected to reach $886.4 million by 2030 growing at a CAGR of 14.3% during the forecast period. miRNA sequencing is a high-throughput technique used to analyze microRNA (miRNA) expression profiles in a biological sample. It involves isolating and sequencing small RNA molecules to identify and quantify miRNAs, providing insights into gene regulation and cellular processes. miRNA assays are experimental methods to measure the abundance or activity of miRNAs, often using technologies like qRT-PCR, microarrays, or next-generation sequencing. These tools help in understanding the role of miRNAs in diseases, development, and cellular responses.

According to an article published in the National Center for Biotechnology Information (NCBI), in July 2021, early-stage diagnosis of COVID-19 may be identified with 99.9% accuracy by measuring miRNA (miR-195-5p, miR-23a-3p, and miR-423-5p).

Market Dynamics:

Driver:

Growing demand for personalized medicine

The growing demand for personalized medicine is driving the market, as miRNAs play a crucial role in gene regulation and disease mechanisms. By providing insights into individual genetic profiles, miRNA analysis enables targeted therapies and precision treatments. This shift towards personalized medicine fosters advancements in diagnostics, drug development, and patient-specific care, increasing the adoption of miRNA sequencing technologies for tailored healthcare solutions.

Restraint:

Complex data analysis

Complex data analysis in the market poses challenges such as high computational costs, the need for advanced bioinformatics expertise, and potential errors in data interpretation. These complexities can lead to inconsistencies, reduced reproducibility, and difficulties in extracting meaningful biological insights. As a result, it can slow down the adoption of miRNA-based diagnostics and therapies, hindering progress in personalized medicine and clinical applications.

Opportunity:

Increasing prevalence of chronic diseases

The increasing prevalence of chronic diseases is fueling the market, as miRNAs are involved in the regulation of various pathways associated with diseases like cancer, diabetes, and cardiovascular conditions. miRNA analysis helps in early diagnosis, monitoring disease progression, and developing personalized treatment plans. This rising demand for precise diagnostics and therapeutic strategies is driving the growth of miRNA sequencing technologies in chronic disease management and research.

Threat:

High cost of sequencing and analysis

The high cost of sequencing and analysis in the market limits accessibility, especially for smaller research labs and healthcare settings. This financial barrier hinders widespread adoption and implementation of miRNA-based diagnostics and therapies. Additionally, the expense can slow down the pace of research and innovation, delaying potential breakthroughs in personalized medicine and reducing opportunities for improving patient outcomes across various diseases.

Covid-19 Impact:

The COVID-19 pandemic disrupted the market by delaying research projects, limiting laboratory access, and diverting resources toward immediate pandemic-related needs. This caused setbacks in ongoing studies and hindered the development of miRNA-based diagnostics and treatments. However, the pandemic also highlighted the importance of rapid, precise diagnostics, accelerating interest in miRNA technologies for viral infection detection and personalized therapeutic approaches in future global health crises.

The autoimmune disease segment is expected to be the largest during the forecast period

The autoimmune disease segment is expected to account for the largest market share during the forecast period. miRNAs are being studied as potential biomarkers for autoimmune disorders like lupus, and multiple sclerosis. miRNA profiling aids in understanding disease mechanisms, identifying therapeutic targets, and developing early diagnostic tools. As research advances, miRNA-based assays are expected to play a key role in the personalized treatment of autoimmune diseases, enhancing diagnostic accuracy and therapeutic efficacy.

The pharmaceutical and biotechnology companies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the pharmaceutical and biotechnology companies segment is predicted to witness the highest growth rate. miRNAs play a crucial role in gene regulation, and their expression profiles can reveal insights into various diseases, including cancer and neurological disorders. Advances in sequencing technologies enable high-throughput analysis of miRNA expression, offering potential for novel therapeutic approaches and improving patient-specific treatment strategies in the pharmaceutical market.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share driven by advanced healthcare infrastructureand a strong focus on personalized medicine. The region benefits from widespread adoption of miRNA technologies in both academic and clinical settings, with ongoing advancements in cancer research, infectious diseases, and genetic disorders. Government funding, along with collaborations between biotech companies and research institutions, further supports the market's expansion.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR. There is a growing investment in miRNA-based research, particularly in understanding their role in gene regulation, disease mechanisms, and therapeutic applications. Additionally, The shift toward personalized and precision medicine is boosting the demand for miRNA sequencing, as miRNAs can offer valuable insights into individual genetic profiles and disease susceptibility.

Key players in the market

Some of the key players in miRNA Sequencing and Assay market include Illumina, Inc., Thermo Fisher Scientific, Inc., Qiagen N.V., Agilent Technologies, Inc., Macrogen, Inc., Bio-Rad Laboratories, Inc., Takara Bio, Inc., Exiqon A/S, Zymo Research Corporation, New England Biolabs, Inc., Roche Diagnostics, Promega Corporation, Luminex Corporation, Boster Biological Technology, and Bioo Scientific.

Key Developments:

In November 2024, QIAGEN announced the launch of two new tools for designing and ordering custom solutions that can be used to support microbial analysis of bacterial, fungal and viral targets. hese new tools enable researchers to customize their assays and panels for use on the QIAcuity digital PCR system as well as on any third-party next-generation sequencing (NGS) system.

In September 2024, QIAGEN announced an important milestone with the launch of 100 new assays for its digital PCR (dPCR) platform QIAcuity for use in the study of cancer, inherited genetic disorders, infectious disease surveillance, and food and environmental monitoring.

Product Types Covered:

  • miRNA Analysis Software
  • miRNA Sequencing Services
  • Other Product Types

miRNA Types Covered:

  • Conserved miRNAs
  • Non-Conserved miRNAs
  • OncomiRs
  • Developmental miRNAs

Sample Types Covered:

  • Blood/Serum/Plasma
  • Tissue Samples
  • Urine and Saliva
  • Cell Lines

Technologies Covered:

  • Sequencing
  • Nanopore Sequencing
  • Sanger Sequencing.
  • Single Molecule Real-time (SMRT) Sequencing

Applications Covered:

  • Cancer
  • Polyglutamine Diseases
  • Cardiovascular Diseases
  • Schizophrenia
  • Autoimmune Disease
  • Infectious Diseases
  • Neurological Disorders
  • Other Applications

End Users Covered:

  • Academic and Research Institutes
  • Pharmaceutical and Biotechnology Companies
  • Hospitals and Diagnostic Laboratories
  • Contract Research Organizations (CROs)
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global miRNA Sequencing and Assay Market, By Product Type

  • 5.1 Introduction
  • 5.2 miRNA Analysis Software
    • 5.2.1 Sequencing Consumables
    • 5.2.2 Library Preparation Kits
  • 5.3 miRNA Sequencing Services
  • 5.4 Other Product Types

6 Global miRNA Sequencing and Assay Market, By miRNA Type

  • 6.1 Introduction
  • 6.2 Conserved miRNAs
  • 6.3 Non-Conserved miRNAs
  • 6.4 OncomiRs
  • 6.5 Developmental miRNAs

7 Global miRNA Sequencing and Assay Market, By Sample Type

  • 7.1 Introduction
  • 7.2 Blood/Serum/Plasma
  • 7.3 Tissue Samples
  • 7.4 Urine and Saliva
  • 7.5 Cell Lines

8 Global miRNA Sequencing and Assay Market, By Technology

  • 8.1 Introduction
  • 8.2 Sequencing
    • 8.2.1 Next-Generation Sequencing (NGS)
    • 8.2.2 Microarray
    • 8.2.3 Quantitative Polymerase Chain Reaction (qPCR)
  • 8.3 Nanopore Sequencing
  • 8.4 Sanger Sequencing.
  • 8.5 Single Molecule Real-time (SMRT) Sequencing

9 Global miRNA Sequencing and Assay Market, By Application

  • 9.1 Introduction
  • 9.2 Cancer
  • 9.3 Polyglutamine Diseases
  • 9.4 Cardiovascular Diseases
  • 9.5 Schizophrenia
  • 9.6 Autoimmune Disease
  • 9.7 Infectious Diseases
  • 9.8 Neurological Disorders
  • 9.9 Other Applications

10 Global miRNA Sequencing and Assay Market, By End User

  • 10.1 Introduction
  • 10.2 Academic and Research Institutes
  • 10.3 Pharmaceutical and Biotechnology Companies
  • 10.4 Hospitals and Diagnostic Laboratories
  • 10.5 Contract Research Organizations (CROs)
  • 10.6 Other End Users

11 Global miRNA Sequencing and Assay Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Illumina, Inc.
  • 13.2 Thermo Fisher Scientific, Inc.
  • 13.3 Qiagen N.V.
  • 13.4 Agilent Technologies, Inc.
  • 13.5 Macrogen, Inc.
  • 13.6 Bio-Rad Laboratories, Inc.
  • 13.7 Takara Bio, Inc.
  • 13.8 Exiqon A/S
  • 13.9 Zymo Research Corporation
  • 13.10 New England Biolabs, Inc.
  • 13.11 Roche Diagnostics
  • 13.12 Promega Corporation
  • 13.13 Luminex Corporation
  • 13.14 Boster Biological Technology
  • 13.15 Bioo Scientific

List of Tables

  • Table 1 Global miRNA Sequencing and Assay Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global miRNA Sequencing and Assay Market Outlook, By Product Type (2022-2030) ($MN)
  • Table 3 Global miRNA Sequencing and Assay Market Outlook, By miRNA Analysis Software (2022-2030) ($MN)
  • Table 4 Global miRNA Sequencing and Assay Market Outlook, By Sequencing Consumables (2022-2030) ($MN)
  • Table 5 Global miRNA Sequencing and Assay Market Outlook, By Library Preparation Kits (2022-2030) ($MN)
  • Table 6 Global miRNA Sequencing and Assay Market Outlook, By miRNA Sequencing Services (2022-2030) ($MN)
  • Table 7 Global miRNA Sequencing and Assay Market Outlook, By Other Product Types (2022-2030) ($MN)
  • Table 8 Global miRNA Sequencing and Assay Market Outlook, By miRNA Type (2022-2030) ($MN)
  • Table 9 Global miRNA Sequencing and Assay Market Outlook, By Conserved miRNAs (2022-2030) ($MN)
  • Table 10 Global miRNA Sequencing and Assay Market Outlook, By Non-Conserved miRNAs (2022-2030) ($MN)
  • Table 11 Global miRNA Sequencing and Assay Market Outlook, By OncomiRs (2022-2030) ($MN)
  • Table 12 Global miRNA Sequencing and Assay Market Outlook, By Developmental miRNAs (2022-2030) ($MN)
  • Table 13 Global miRNA Sequencing and Assay Market Outlook, By Sample Type (2022-2030) ($MN)
  • Table 14 Global miRNA Sequencing and Assay Market Outlook, By Blood/Serum/Plasma (2022-2030) ($MN)
  • Table 15 Global miRNA Sequencing and Assay Market Outlook, By Tissue Samples (2022-2030) ($MN)
  • Table 16 Global miRNA Sequencing and Assay Market Outlook, By Urine and Saliva (2022-2030) ($MN)
  • Table 17 Global miRNA Sequencing and Assay Market Outlook, By Cell Lines (2022-2030) ($MN)
  • Table 18 Global miRNA Sequencing and Assay Market Outlook, By Technology (2022-2030) ($MN)
  • Table 19 Global miRNA Sequencing and Assay Market Outlook, By Sequencing (2022-2030) ($MN)
  • Table 20 Global miRNA Sequencing and Assay Market Outlook, By Next-Generation Sequencing (NGS) (2022-2030) ($MN)
  • Table 21 Global miRNA Sequencing and Assay Market Outlook, By Microarray (2022-2030) ($MN)
  • Table 22 Global miRNA Sequencing and Assay Market Outlook, By Quantitative Polymerase Chain Reaction (qPCR) (2022-2030) ($MN)
  • Table 23 Global miRNA Sequencing and Assay Market Outlook, By Nanopore Sequencing (2022-2030) ($MN)
  • Table 24 Global miRNA Sequencing and Assay Market Outlook, By Sanger Sequencing. (2022-2030) ($MN)
  • Table 25 Global miRNA Sequencing and Assay Market Outlook, By Single Molecule Real-time (SMRT) Sequencing (2022-2030) ($MN)
  • Table 26 Global miRNA Sequencing and Assay Market Outlook, By Application (2022-2030) ($MN)
  • Table 27 Global miRNA Sequencing and Assay Market Outlook, By Cancer (2022-2030) ($MN)
  • Table 28 Global miRNA Sequencing and Assay Market Outlook, By Polyglutamine Diseases (2022-2030) ($MN)
  • Table 29 Global miRNA Sequencing and Assay Market Outlook, By Cardiovascular Diseases (2022-2030) ($MN)
  • Table 30 Global miRNA Sequencing and Assay Market Outlook, By Schizophrenia (2022-2030) ($MN)
  • Table 31 Global miRNA Sequencing and Assay Market Outlook, By Autoimmune Disease (2022-2030) ($MN)
  • Table 32 Global miRNA Sequencing and Assay Market Outlook, By Infectious Diseases (2022-2030) ($MN)
  • Table 33 Global miRNA Sequencing and Assay Market Outlook, By Neurological Disorders (2022-2030) ($MN)
  • Table 34 Global miRNA Sequencing and Assay Market Outlook, By Other Applications (2022-2030) ($MN)
  • Table 35 Global miRNA Sequencing and Assay Market Outlook, By End User (2022-2030) ($MN)
  • Table 36 Global miRNA Sequencing and Assay Market Outlook, By Academic and Research Institutes (2022-2030) ($MN)
  • Table 37 Global miRNA Sequencing and Assay Market Outlook, By Pharmaceutical and Biotechnology Companies (2022-2030) ($MN)
  • Table 38 Global miRNA Sequencing and Assay Market Outlook, By Hospitals and Diagnostic Laboratories (2022-2030) ($MN)
  • Table 39 Global miRNA Sequencing and Assay Market Outlook, By Contract Research Organizations (CROs) (2022-2030) ($MN)
  • Table 40 Global miRNA Sequencing and Assay Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.